EXACT Therapeutics announces first half 2024 interim results

30 Sep 2024 08:00 CEST

30 September, 2024: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a
clinical stage precision health company utilising Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today announces its interim results
for the first half 2024.

The interim report and presentation for the first half year 2024 are also
available on the company's website: www.exact-tx.com.

For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

John M. Edminson
CFO EXACT Therapeutics
Email: john.edminson@exact-tx.com


About EXACT-Tx

EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement – Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement – with the potential to enable or significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy) and brain
diseases. www.exact-tx.com

About ACT®
• ACT is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.

• ACT is being tested in the clinic and has released positive interim data. It
is supported by a strong and broad preclinical package demonstrating therapeutic
enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as
well as blood-brain barrier penetration.

• Initial focus of the Company is oncology. The ACT platform has potential
across many therapeutic areas (including CNS, immunotherapy) and product
classes.

Forward looking statements:

This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

628744_1 H 2024 report - EXACT Therapeutics AS.pdf